## Bachem Scales Up Global Production: Major Capacity Investment Signals Growth Strategy Through 2030

Bachem, the Swiss peptide and oligonucleotide manufacturing leader, is moving forward with substantial capacity expansion initiatives that underscore its commitment to serving the pharmaceutical and biotech sectors. The company's multi-year development roadmap involves strategic investments and facility modernization spanning North America and Europe.

### Bubendorf Facility Reaches Critical Milestone

The Building K inspection by local regulatory authorities (RHI) in Bubendorf has cleared a significant hurdle for the manufacturing company. Feedback from the authorities confirms the project timeline remains on track without anticipated delays. Production of initial GMP batches is targeted for 2025, with commercial-scale output ramping throughout 2026 while construction activities continue in other sections of the facility. This production hub will employ approximately 350 workers and deliver multiple tons of peptide products annually—a substantial contribution to global pharmaceutical supply chains.

Building K stands as Bachem's most ambitious undertaking to date and represents one of the world's most technologically advanced peptide manufacturing complexes. The facility represents the company's response to increasing demand for high-quality peptide therapeutics in clinical and commercial applications.

### US Market Expansion and Strategic Asset Acquisition

In Vista, California, Bachem has acquired adjacent property to its current operations, positioning the company for downstream and upstream capacity additions. This acquisition reflects the company's broader strategy to strengthen its footprint in the United States—a market that represents the largest healthcare opportunity globally.

Between 2026 and 2030, Bachem plans to deploy approximately USD 250 million across US operations. The investment encompasses Vista facility transformation and modernization efforts at its Torrance location, demonstrating a coordinated approach to production efficiency across multiple US sites.

### Management Perspective on Strategic Positioning

Thomas Meier, Chief Executive Officer, emphasized the company's momentum: "Our capacity expansion trajectory reflects Bachem's operational discipline and market positioning. Building K's completion and the Vista property acquisition position us to meet pharmaceutical industry demand while enhancing our commercial partnerships across the United States."

### Company Overview

Bachem operates as an innovation-focused enterprise with more than five decades of experience in peptide and oligonucleotide development and production. The organization serves pharmaceutical and biotechnology firms worldwide through research-stage products, clinical-phase support, and commercial-scale manufacturing. Bachem maintains a global presence with headquarters in Switzerland and operational locations spanning Europe, North America, and Asia. The company is publicly listed on the SIX Swiss Exchange and continues to strengthen its investor relations communications regarding strategic developments.